Latest BIIB34 news and sentiment

Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data

Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track record. Progress with Alzheimer's treatment LEQEMBI and pipeline assets such as the zorevunersen program for Dra

Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet

On August 6, Biogen (NASDAQ:BIIB) completed its acquisition of RayThera, a privately held biotech developing small-molecule immunology therapies whose lead program entered Phase 1 trials in July 2026. The deal lands just over a week after the company posted a second-quarter beat that sent shares up nearly 5% on July 29. Together, the two moments capture where Biogen stands right now: a company reshaping itself around newer growth engines while still carrying the weight of its aging multiple sclerosis business.Biogen's (BIIB) Immunology Bet Meets A Pricier Balance Sheet A Pipeline Getting Real

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– –Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile– –New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life– BEDFORD, Mass. & CAMBRIDGE, Mass., September 01, 2026--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protei

Veeva Vault CRM Selected by Biogen

Unified commercial platform to help speed the delivery of medicines to patients PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Biogen "We are honored to provide Vault CRM as the agentic commercial foundation for Biogen as it delivers medicines that transform patients' lives," said Tom Schwenger, president and CCO at Veeva. "Bringing complex treatments to market requires a highly adaptive commercial strategy, and we are committed to providing the advanced capabilities

Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation

Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the company's late-stage pipeline offers significant upside that is not fully reflected in current valuations. The firm highlighted litifilimab and felzartamab as key assets, with clinical readouts expected over the coming year. Wolfe said litifilimab could become the first biologic approved for cut

Projeções de Resultados: Biogen Inc (BIIB) — LPA e Crescimento de Receita

Biogen Completes Acquisition of RayThera Inc.

CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. The acquisition strengthens Biogen’s growing immunology portfolio, adding multiple assets that have potential to treat immune-mediated conditions across a range of indications. The lead program entered Phase 1 development in July 2026. “We are excited about the potential of these immunology assets as we continue to strengthen and dive

Form 144 BIOGEN INC. For: 3 August By Investing.com

Biogen Stock: How To Find & Own America's Greatest Opportunities

Biogen is one of the oldest and most venerable biotechs. For a time in the late 1990s, Biogen's share price grew ninefold. Continue Reading